Clinical Trials
54 trialsResimmune®
Virogen Biotechnology Inc.
EPIC
Therakos LLC
Intravenous Iron in Combination With Standard of Care Immunotherapy in Melanoma
Indiana University
Study of Two Dose Levels of RTA 402 in Patients With Advanced Malignant Melanoma
Biogen
Immunotherapy Before Transplantation for Skin Cancer Prevention in Organ Transplant Recipients
Massachusetts General Hospital
Immunotherapy After Transplantation for Skin Cancer Prevention in Organ Transplant Recipients
Massachusetts General Hospital
ECT-Pembrolizumab in Patients With Unresectable Melanoma With Superficial or Superficial and Visceral Metastases
European Institute of Oncology
Clinical Trial of TJ271 Injection Combined With Pembrolizumab in the Treatment of Advanced Solid Tumors
TJ Biopharma Co., Ltd.
SUMMIST
Vastra Gotaland Region
Olaparib in Unresectable/Metastatic Melanoma With BRCA1/2
Dana-Farber Cancer Institute
Psilocybin-Assisted Psychotherapy for Anxiety in People With Stage IV Melanoma
Multidisciplinary Association for Psychedelic Studies
Brentuximab Vedotin and Pembrolizumab in Treating Patients With Recurrent Peripheral T-Cell Lymphoma
Northwestern University
"Dabrafenib and Trametinib in Circulating Free DNA BRAFV600 Mutated Metastatic Melanoma Patients: a Prospective Phase II, Open Label, Multicentre Study - (Bioliquid TAILOR Study - BIOTAILOR)"
Fondazione Melanoma Onlus
A Study of ONCOS-102 in Combination With Other Novel Immune-therapies in Advanced Treatment-resistant Melanoma Patients
Targovax ASA
GR-MD-02 + Pembrolizumab Versus Pembrolizumab Monotherapy in Melanoma and Squamous Cell Head and Neck Cancer Patients
Providence Health & Services
Sargramostim (GM-CSF) + PD-1
Dana-Farber Cancer Institute
A Study of Nivolumab Intravenous (IV) to Subcutaneous (SC) Switch in Adjuvant Melanoma and Bladder Cancer
Bristol-Myers Squibb
PUTNET
Excel Diagnostics and Nuclear Oncology Center
INTRANS
Melanoma Institute Australia
Domatinostat in Combination With Avelumab in Patients With Treatment-naïve Metastatic Merkel Cell Carcinoma (MERKLIN 1)
4SC AG
Study of Neoadjuvant Imprime PGG and Pembrolizumab for Stage III, Resectable Melanoma
HiberCell, Inc.
PROMPT
European Organisation for Research and Treatment of Cancer - EORTC
SBRT as a Vaccination for Metastatic Melanoma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
CheckMate 7UA
Bristol-Myers Squibb
Phase II Study of Nivolumab in Combination With Radiation Therapy as Definitive Treatment for Patients With Locally Advanced, Unresectable Head and Neck Mucosal Melanoma.
Samsung Medical Center
Neoadjuvant Use of Talimogene Laherparepvec and BRAF/MEK Inhibitor for Advanced Nodal BRAF Mutant Melanoma
TriHealth Inc.
SAbR Plus Ipilimumab Plus Nivolumab in Metastatic Melanoma Patients
University of Texas Southwestern Medical Center
Intermittent LGX818 and MEK162 in Treating Patients With Metastatic Melanoma Who Have BRAFV600 Mutations
Jonsson Comprehensive Cancer Center
CEDUVEAL-M
Grupo Español Multidisciplinar de Melanoma
Trial of Outpatient Intravenous Interleukin-2 in Malignant Melanoma and Metastatic Kidney Cancer
Loma Linda University
A Phase II Trial of Neoadjuvant Treatment With PD-1 Inhibition (Nivolumab) With or Without IDO Inhibition (BMS-986205) and With or Without CTLA-4 Inhibition (Ipilimumab) in Resectable Stage III or IV Melanoma
Dana-Farber Cancer Institute
Study Of Intratumoral G100 In Cutaneous T Cell Lymphoma
Yale University
Nivolumab With Vismodegib in Patients With Basal Cell Nevus Syndrome
Columbia University
Study of the Drug Ipilimumab for Metastatic Merkel Cell Carcinoma
National Institutes of Health Clinical Center (CC)
Vaccine Therapy and GM-CSF in Treating Patients With CNS Lymphoma
University of Texas Southwestern Medical Center
An Investigational Study of Infliximab With Prednisone or Methylprednisolone Versus Prednisone Combination Treatment in Immune Related or Severe Diarrhea in Patients Treated With Yervoy and/or Opdivo
Bristol-Myers Squibb
Nivolumab or Expectant Observation Following Ipilimumab, Nivolumab, and Surgery in Treating Patients With High Risk Localized, Locoregionally Advanced, or Recurrent Mucosal Melanoma
National Cancer Institute (NCI)
Efficacy and Safety Study of GSK1120212, a MEK Inhibitor, in Subjects With Uveal Melanoma
GlaxoSmithKline
Low-dose Cyclophosphamide and Outpatient IV Interleukin-2 in Metastatic Melanoma
Western Regional Medical Center
A Phase II Trial of Sunitinib and Nivolumab for KIT-mutated Advanced Melanoma
California Pacific Medical Center Research Institute
Single or Double Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Hematologic Malignancies
Rutgers, The State University of New Jersey
Biomarker Correlates of Hypoxia in Metastatic Melanoma
H. Lee Moffitt Cancer Center and Research Institute
Therapeutic Efficacy of Topical Sirolimus in Early Stage Cutaneous T-cell Lymphoma (CTCL)
Medical College of Wisconsin
Sorafenib and Temsirolimus in Treating Patients With Metastatic, Recurrent, or Unresectable Melanoma
National Cancer Institute (NCI)
Study to Determine Efficacy and Safety of CC-486 With Nab-Paclitaxel Versus Nab-Paclitaxel in Patients With Chemotherapy naïve Metastatic Melanoma
Celgene
Antineoplaston Therapy in Treating Patients With Neuroendocrine Tumor That Is Metastatic or Unlikely to Respond to Surgery or Radiation Therapy
National Cancer Institute (NCI)
Ipilimumab With or Without Vaccine Therapy in Treating Patients With Previously Treated Stage IV Melanoma
Bristol-Myers Squibb
Celecoxib in Preventing Skin Cancer
National Cancer Institute (NCI)
Study of Immune Responses in Patients With Metastatic Melanoma
Providence Health & Services
RO4929097 in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Melanoma That Can Be Removed by Surgery
National Cancer Institute (NCI)